rollupTree
The recursive-computation engine under massProps grows the accessors its consumer needed
A side-by-side editorial comparison of mLLMCelltype and PEIMAN2 — release velocity, themes, recent moves, and the top alternatives to consider.
Consensus cell-type annotation that keeps adding LLM providers, and keeps fixing how they fail.
mLLMCelltype annotates scRNA-seq clusters by polling several LLMs and reconciling their answers into a consensus label, shipping as paired R and Python packages. The 2.0 line has settled into a rhythm: broaden the provider roster, then harden the parsing and retry paths that decide whether a given provider's answer survives into the consensus. Version 2.0.8 is pure reliability work, disabling DeepSeek V4's thinking mode because it exhausted the response budget before labels were returned, and raising non-streaming timeouts to 120 seconds.
PEIMAN2 cut its annotation database loose from its release cycle without breaking CRAN.
PEIMAN2 does enrichment analysis over post-translational modifications, testing whether a protein list is enriched for particular PTMs against UniProt-derived annotations, with translation functions bridging to mass spectrometry workflows. Its answers are only as current as its bundled database, and until June that database could only be refreshed by releasing a new package version. Version 1.1.0 changes that.
mLLMCelltype annotates scRNA-seq clusters by polling several LLMs and reconciling their answers into a consensus label, shipping as paired R and Python packages. The 2.0 line has settled into a rhythm: broaden the provider roster, then harden the parsing and retry paths that decide whether a given provider's answer survives into the consensus. Version 2.0.8 is pure reliability work, disabling DeepSeek V4's thinking mode because it exhausted the response budget before labels were returned, and raising non-streaming timeouts to 120 seconds.
The centre of gravity has moved from adding models to defending against them. Recent notes read as a catalogue of ways an LLM response can be malformed: numbered lists, preamble headers, annotation-internal colons, a mid-list Unknown, thinking blocks that precede the answer, rate limits returned as HTTP 200 with an error buried in the body. Each of those could previously shift or drop a cluster's annotation, which for a consensus tool is the failure that matters most. Provider additions now land as routine catalogue growth rather than a change in what the package can do.
Expect the next release to continue the reliability arc with more provider-specific timeout and parsing guards, and a CRAN publication of 2.0.8 to close the gap the notes themselves flag. Whether return_reasoning grows from an option into the default per-cluster evidence record is the open question these entries do not yet answer.
PEIMAN2 does enrichment analysis over post-translational modifications, testing whether a protein list is enriched for particular PTMs against UniProt-derived annotations, with translation functions bridging to mass spectrometry workflows. Its answers are only as current as its bundled database, and until June that database could only be refreshed by releasing a new package version. Version 1.1.0 changes that.
The package has been moving from a fixed snapshot toward versioned, user-selectable data. Earlier releases updated the bundled database in place — 1.0.0 shipped the March 2025 version and said little else — which meant the annotation vintage was whatever the package version implied. Now update_peiman_database() downloads and caches external database files and UniProt PTM lists, enrichment workflows take a database_version argument, and the mass-spec translators take a ptmlist_version, so an analysis can pin a dated database rather than a package release. The CRAN-safe default is preserved deliberately: loading, examples and checks still use the bundled internal data and need no network.
Version pinning is now expressible but the release notes do not describe how a chosen version is recorded in output, so surfacing the active database version in results is the natural companion. The database and the UniProt PTM list are versioned separately, which leaves room for a combined manifest.
Other Infra & APIs products tracked by Sparkpulse, ranked by recent ship velocity. Each card links to a full editorial trajectory and lets you pivot into a head-to-head comparison with either mLLMCelltype or PEIMAN2.
The recursive-computation engine under massProps grows the accessors its consumer needed
A mass-properties rollup spends a year on documentation and follows its sibling's API
Six months of releases and not one of them touched the scoring models
A cognitive-science sampling package ships once, then goes quiet for eighteen months
A Bayesian volatility sampler in its maintenance decade, paying for its own speed
A black-box interpreter reaches CRAN, then learns multi-class and survival responses
See all mLLMCelltype alternatives → · See all PEIMAN2 alternatives →
Latest ship moves from both products, interleaved chronologically. ⚡ = editorial spark.
They serve adjacent needs but don't currently overlap on shipped themes. mLLMCelltype is currently shipping more aggressively (velocity 2.5 vs 0.0), with 0 editorial sparks in the last 30 days against 0. See the at-a-glance table above for a side-by-side breakdown of velocity, recent sparks, and editorial themes.
Sparkpulse doesn't pick a winner — we score release velocity, not feature parity. mLLMCelltype is currently shipping more aggressively (velocity 2.5 vs 0.0), with 0 editorial sparks in the last 30 days against 0. For your specific use case, the alternatives sections above list other Infra & APIs products to evaluate alongside.
Top mLLMCelltype alternatives in Infra & APIs are ranked by recent ship velocity. Browse the "mLLMCelltype alternatives" section above for the current picks, or visit /alternatives/mllmcelltype for the full list with editorial commentary on each.
Top PEIMAN2 alternatives in Infra & APIs are ranked by recent ship velocity. Browse the "PEIMAN2 alternatives" section above for the current picks, or visit /alternatives/peiman2 for the full list with editorial commentary on each.